Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum Biopharma Ltd. received an amended Schedule 13G/A (Amendment No. 8) from Malone Wealth Ventures LLC reporting substantial ownership of its common stock. Malone Wealth Ventures reports beneficial ownership of 375,752 shares, representing 9.8% of the outstanding common shares.
The firm has sole power to vote 92,180 shares and sole power to dispose of 375,752 shares. The filing explains that these securities are held for clients of Malone Wealth Ventures, who have rights to dividends and sale proceeds, and states the holdings are in the ordinary course of business, not to influence control of the company.
Quantum Biopharma Ltd. filed an amended foreign issuer report to add a previously issued press release as an exhibit. The release announces the termination of its October 31, 2025 at-the-market offering agreement with H.C. Wainwright & Co., and is described in the exhibit index as relating to the closing of a private placement and a corporate update. Aside from furnishing this exhibit, the company states that the original report’s disclosures are unchanged.
Quantum Biopharma Ltd. has furnished a Form 6-K that provides investors with access to its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024, attached as Exhibit 99.1.
The filing also includes Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same periods as Exhibit 99.2, CEO and CFO certificates, and full Inline XBRL files. These materials are incorporated by reference into the company’s existing Form F-3 registration statement.
Quantum BioPharma Ltd. furnished a Form 6-K announcing it entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC to permit sales of its Class B Subordinate Voting Shares. A Canadian counsel legal opinion on the validity of the shares and the ATM agreement are attached as exhibits and incorporated by reference into the company’s Form F-3 (File No. 333-276264).
Quantum BioPharma Ltd. (QNTM) launched a primary at-the-market (ATM) offering of up to US$21,225,000 of Class B Subordinate Voting Shares under a Sales Agreement with H.C. Wainwright & Co., acting as sales agent or principal. Sales may be made from time to time on Nasdaq or through other permitted methods, after the company delivers sales notices.
The company will pay a 3.0% commission on gross proceeds to the sales agent and intends to use any net proceeds for working capital and general corporate purposes. No sales will be made in Canada or over the facilities of the CSE or other Canadian markets. The shares trade as “QNTM” on Nasdaq and the CSE, and “0K91” on Frankfurt.
As disclosed for Form F‑3 eligibility, the company’s public float was approximately US$67,723,261, and, after US$1,326,147 sold in the prior 12 months, it states capacity to sell up to US$21,248,272 under General Instruction I.B.5 so long as the float remains below US$75.0 million. The filing highlights risks typical of ATM programs, including potential dilution, price variability during sales, reliance on management’s broad use of proceeds discretion, PFIC tax considerations for U.S. holders, Nasdaq listing compliance risk, and volatility tied to its cryptocurrency treasury investments.